Journal of Clinical Neurology · 2022 · 13 citations · 8 references
MedicinePediatricsPharmacologyBehavioral PharmacologyEpilepsyEpileptologyAntiepileptic PharmacologyAntiepileptic PharmacotherapyAntiseizure MedicationsCannabinoid PharmacologyEpilepsy In ChildhoodEpilepsy SyndromesAdaptive Behavior ProfilesOpen-label TrialsPediatric Antiepileptic TherapyPediatric Epilepsy PharmacotherapyTreatment Outcomes In EpilepsyTreatment-resistant EpilepsyTreatment-resistant SeizuresVineland Adaptive Behavior Scales
BACKGROUND AND PURPOSE: Data regarding the effects of cannabidiol (CBD) on the quality of life (QOL) are currently inadequate. We assessed the QOL of pediatric patients with epilepsy who were treated with CBD. METHODS: This prospective, open-label study included pediatric and adolescent patients (aged 2-18 years) with Dravet syndrome or Lennox-Gastaut syndrome. Oral CBD was administered at 10 mg/kg/day. The Korean version of the Quality Of Life in Childhood Epilepsy (QOLCE) questionnaire was administered when CBD treatment began and again after 6 months. Adaptive behavior was measured using the Korean versions of the Child Behavior Checklist (K-CBCL) and the second edition of the Vineland Adaptive Behavior Scales (Vineland-II). RESULTS: =0.005). No other Vineland-II scores and no K-CBCL scores had changed after 6 months of CBD treatment. CONCLUSIONS: CBD is an efficacious antiseizure drug used to treat Dravet syndrome and Lennox-Gastaut syndrome. However, it did not improve the patient QOL in our study, possibly because all of our patients had profound intellectual disabilities.
8
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky, J. Helen Cross, Linda Laux et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text